Bremelanotide
Also known as: PT-141, Vyleesi
FDA-approved melanocortin receptor agonist for female hypoactive sexual desire disorder.
Benefits
6
Conditions
5
Evidence
Phase 3 RCTs, FDA approved for female HSDD+ studies
Source
Synthetic melanocortin receptor agonist (PT-141 is the research name)
Gabriel Brain Score
Moderate
Overview
FDA-approved melanocortin receptor agonist for female hypoactive sexual desire disorder.
Mechanism of Action
Activates MC3R and MC4R melanocortin receptors in hypothalamus and spinal cord, increases sexual desire via central dopaminergic pathways, works independently of vascular mechanisms, modulates sexual arousal centers in brain.
Key Benefits
- ✓Increases sexual desire and arousal
- ✓Works centrally (brain-based)
- ✓Effective for both sexes
- ✓Independent of vascular function
- ✓Rapid onset (30-45 minutes)
- ✓No dependency issues
Clinical Applications
Dosing Guidelines
Subcutaneous injection
* Dosing should be individualized. Always consult with a qualified healthcare practitioner.
Research & Evidence
Phase 3 RCTs, FDA approved for female HSDD
FDA approved based on RECONNECT trials showing improved sexual desire in premenopausal women. Clinical evidence in both sexes. Unique central mechanism compared to peripheral vasodilators.
Safety Information
Potential Side Effects
- •Nausea (common)
- •Flushing
- •Headache
- •Transient hypertension
- •Injection site reactions
Contraindications
- Uncontrolled hypertension
- Cardiovascular disease
- Pregnancy
- Breastfeeding
Interactions
- ⚠Caution with antihypertensives
- ⚠Avoid alcohol (increases hypotension risk)